The Nuclear Medicine Full-Chain High-Quality Development Empowerment Training Program Was Successfully Held in Mianyang, Sichuan

From September 6 to 11, the Nuclear Medicine Full-Chain High-Quality Development Empowerment Training Program, hosted by the Department of Human Resources and Social Security of Sichuan Province and organized by Mianyang Central Hospital, was successfully held in Mianyang, Sichuan. Hundreds of nuclear medicine peers from all over the country, including Beijing, Shanghai, Guangzhou, Tianjin, Chongqing, and Chengdu, completed all course studies and returned to their posts fully loaded with training results. This training was hosted by the Department of Human Resources and Social Security of Sichuan Province, organized by Mianyang Central Hospital, and co-organized by multiple departments including the Mianyang Municipal Human Resources and Social Security Bureau and the Fourth Division of Science and Technology Innovation and Industrial Innovation Integration Development of Mianyang Science and Technology City. The training content focused on nuclear medicine from laboratory research and development to clinical application...

2026-09-14

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Promotes the Translation and Application of Medical X-ray Skin Protective Agent

On September 10, Zhang Jianhong, Party Secretary of the Institute of Radiation Medicine, Chinese Academy of Medical Sciences, led a delegation to Nanjing to conduct research with the Institute of Dermatology, Chinese Academy of Medical Sciences and Jiangsu Haizhi Biomedical Co., Ltd., exchanging views on the translation and application of the medical X-ray skin protective agent project. Representatives from the hospital, research institute, and enterprise held discussions on industry-university-research collaboration, clinical demand alignment, and industrialization pathways. It is understood that the medical X-ray skin protective agent is one of the core products in the radiation protection series independently developed by the Institute of Radiation Medicine. After being put into production, the product is expected to become China's first medical X-ray skin protective agent for scar radiotherapy. At the symposium, Zhang Jianhong stated that dermatology...

2026-09-12

Best Cyclotron Systems 70MeV high-current proton cyclotron passes factory acceptance test, to be delivered to Taiwan, China

Best Cyclotron Systems (BCS) recently announced that its 70 megaelectronvolt (MeV) high-current proton cyclotron B-70 completed factory acceptance testing in July, and the equipment will soon be delivered to the National Atomic Research Institute (NARI) in Taoyuan City, Taiwan, China. Related installation and project construction are expected to be completed in 2027. According to the introduction, B-70 was designed, developed and manufactured in Canada by engineers and scientists under TeamBest, and is an advanced cyclotron system for high-current proton beam applications. The equipment will be used to expand accelerator-based radioisotope production and research capabilities, and also reflects the company's...

2026-09-11

Denmark's Region East Denmark to expand Sectra One imaging platform, unifying regional nuclear medicine and other medical imaging services

Swedish medical imaging IT and cybersecurity company Sectra has recently signed a contract to expand the application of its Sectra One enterprise imaging solution from hospitals in Denmark's Capital Region to the entire Region East Denmark. Region East Denmark was formed by merging the Capital Region and Region Zealand, and this expansion aims to promote unified operation of imaging services across hospitals in the entire region. Under the contract, Sectra One will be delivered as a fully managed cloud service, covering all hospitals in Region East Denmark for the review and storage of radiology medical images, including breast imaging, nuclear medicine, and clinical physiology. Hospitals in Region Zealand will migrate to the system currently in use in the Capital Region,...

2026-09-11

Canada Supports IAEA "Rays of Hope" Initiative for the First Time, Will Provide Medical Isotope Training for Latin America

The Canadian Nuclear Isotope Council (CNIC) announced on September 10 that Canada has for the first time formally provided support to the International Atomic Energy Agency (IAEA) Rays of Hope initiative, and will help enhance cancer diagnosis and treatment capacity in Latin America through training in the production of medical radioisotopes and radiopharmaceuticals. The Rays of Hope initiative aims to expand access to cancer treatment and radiotherapy infrastructure in low- and middle-income countries. Under the arrangement, from November 8 to 14, 26 relevant sector leaders from Argentina, Brazil, Chile and Mexico will travel to Ontario, Canada, to participate in a training program jointly organized by Bruce Power and McMaster University. The training will focus on medical isotopes...

2026-09-11

US Study Says Third Course of Radiation Therapy May Improve Survival and Symptoms in Children with Recurrent DIPG

According to news from the Icahn School of Medicine at Mount Sinai in the United States on September 2, researchers at the institution released a new study on re-irradiation for recurrent diffuse intrinsic pontine glioma (DIPG). The study shows that carefully selected pediatric patients who receive a third course of radiation therapy after disease recurrence may achieve symptom relief, improved quality of life, and potentially prolonged survival. The related study has been published in Practical Radiation Oncology. DIPG is a highly aggressive pediatric brain tumor that occurs in the brainstem region. The brainstem controls critical life functions such as breathing and movement, so the tumor usually cannot be removed surgically. Data show that DIPG mainly affects children aged 5 to 10, and even...

2026-09-10

Rapid Arc Dynamic Precision Radiotherapy Technology Launched in Western New South Wales, Australia

Cancer patients in western New South Wales, Australia, have recently gained a new radiotherapy option. The Western New South Wales Local Health District has introduced Rapid Arc Dynamic (RAD) technology at the Western Cancer Centre at Dubbo Health Service, becoming the first public health institution in Australia to offer this service. According to reports, RAD is a highly precise and personalized radiotherapy technology that can help clinicians more accurately target tumor areas while minimizing radiation exposure to surrounding healthy tissue. This technology is suitable for a variety of treatment scenarios, particularly for patients with longer tumor extents and lymph node metastases. R...

2026-09-10

India's Fortis Healthcare Plans to Introduce the Country's First Upright Proton Therapy System

India's Fortis Healthcare has announced plans to install Mevion Medical Systems' MEVION S250-FIT proton therapy system at Fortis Memorial Research Institute (FMRI) in Gurugram. The hospital is Fortis' flagship quaternary care hospital and its comprehensive oncology and precision cancer treatment center. According to reports, the system will be equipped with Leo Cancer Care's Marie® upright patient positioning and imaging solution, as well as RaySearch Laboratories' RayStation® treatment planning software. If the project receives relevant regulatory approvals and completes site preparation, Fortis will become India's first planned...

2026-09-10

Siemens Healthineers Completes PET Detector Manufacturing Expansion Project in Tennessee, USA

Siemens Healthineers recently completed the expansion and renovation project of its PET detector center in Rockford, Tennessee, USA, with a total investment of $43.6 million. The project aims to enhance PET detector manufacturing capacity to meet the growing demand for PET/CT scanning equipment. The project added 40,000 square feet of building area to the existing 97,000-square-foot campus and renovated 7,500 square feet of existing space. The Rockford facility is Siemens Healthineers' only manufacturing site globally for producing PET detectors used in its PET/CT systems. The expansion includes 36,000 square feet of dedicated manufacturing space and a 4,000-square-foot expansion of R&D facilities; meanwhile, the company also renovated...

2026-09-10

American Society of Nuclear Cardiology Releases New 2026 Guidelines for Stress Testing in SPECT and PET Myocardial Perfusion Imaging

The American Society of Nuclear Cardiology (ASNC) has recently developed and released the "2026 ASNC Guidelines for Stress Testing in SPECT and PET Myocardial Perfusion Imaging." The guidelines have been published online in the Journal of Nuclear Cardiology and will replace the 2016 version to reflect changes in the field of nuclear cardiology over the past decade in terms of technology application, examination workflows, and clinical assessment. The new guidelines focus on stress testing in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) myocardial perfusion imaging, updating recommendations on patient preparation, selection of stress testing modalities, safety management, protocols for different imaging modalities, image interpretation, and report writing. The guideline chair and lead...

2026-09-10

South Korea's First Animal Radiopharmaceutical Approved for the Treatment of Feline Hyperthyroidism

The Korea Atomic Energy Research Institute announced on September 10 that Thyrokitty Injection (I-131), a radiopharmaceutical for the treatment of feline hyperthyroidism developed by the research team led by Dr. Lim Jae-cheong, has obtained an animal drug manufacturing license issued by the Animal and Plant Quarantine Agency of South Korea. This is South Korea's first animal radiopharmaceutical to receive final product approval, marking the transition of related technologies that had previously been mainly at the R&D stage into clinical therapeutic application for pets. Feline hyperthyroidism is a relatively common endocrine disease in older cats, mainly characterized by excessive secretion of thyroid hormones. According to reports, approximately 10% of cats aged 10 and above may suffer from this disease. Traditional treatment methods typically require...

2026-09-10

Domestically Developed "Boron Neutron Capture Therapy System" Enters the National Special Review Procedure for Innovative Medical Devices

Recently, the Medical Device Technical Review Center of the National Medical Products Administration issued a public notice on the review results of applications for the Special Review Procedure for Innovative Medical Devices (No. 14 of 2026). The boron neutron capture therapy system independently developed by Huapeng Neutron Technology (Hangzhou) Co., Ltd. has officially entered the National Special Review Procedure for Innovative Medical Devices after the public notice period. Screenshot from the official website of the Medical Device Technical Review Center of the National Medical Products Administration. The Special Review Procedure for Innovative Medical Devices is a review channel established by the National Medical Products Administration to encourage medical device innovation and promote the application of new technologies, effective since December 1, 2018. According to the relevant procedures, drug regulatory authorities and technical institutions will, on the premise of not lowering standards and not reducing procedures,...

2026-09-10

ITM and SpiroChem Announce Strategic Collaboration to Advance Novel Radiopharmaceutical Development

Garching/Munich, Germany and Basel, Switzerland, September 8, 2026 – Radiopharmaceutical biotechnology company ITM Isotope Technologies Munich SE and Swiss collaborative research organization SpiroChem AG today announced a strategic drug discovery partnership focused on a novel radiopharmaceutical candidate within ITM's pipeline. The specific target and financial terms of the collaboration were not disclosed. Under the agreement, the parties will combine their respective capabilities to advance candidate discovery and optimization. SpiroChem will leverage its drug discovery platform, macrocycle library, and screening engine to lead hit identification and optimization, while ITM will provide...

2026-09-09

Penza State University in Russia Develops Training Simulator for X-ray Image Defect Recognition

Researchers at Penza State University in Russia have developed an interactive training simulator for identifying defects in X-ray images, aimed at helping medical students and residents more accurately assess abnormalities in medical images and understand the physical causes behind different image defects. X-ray image quality directly affects the efficiency of pathological change detection and clinical diagnostic judgment. Factors such as equipment condition, exposure parameters, radiation dose, and quantum noise levels can all lead to degraded image quality. Therefore, radiologic technologists and radiologists need not only to identify lesions in images, but also to assess image quality and determine whether defects such as low contrast, noise, blur, and artifacts may affect diagnosis...

2026-09-09

GE HealthCare's StarGuide GX Digital 4D CZT SPECT/CT Receives FDA 510(k) Clearance in the U.S.

GE HealthCare recently announced that its new digital 4D CZT SPECT/CT system, StarGuide GX, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The system had previously obtained CE marking, and this U.S. clearance marks progress in the clinical adoption of its next-generation molecular imaging technology. Designed for theragnostics and precision medicine needs, StarGuide GX is a comprehensive SPECT/CT system. It supports imaging at multiple energy levels, enables general-purpose SPECT imaging, and is tailored for emerging tracer applications, including investigational α-emitters, aiming to provide imaging support for clinicians and researchers exploring new pathways in diagnosis, treatment planning, and therapeutic response monitoring.

2026-09-09

Australia's First ZAP-X Gyroscopic Radiosurgery Platform to Be Installed at St Vincent's Hospital Sydney

ZAP Surgical Systems has announced that GenesisCare will become the first cancer treatment provider in Australia to introduce the ZAP-X Gyroscopic Radiosurgery® platform. The device is expected to be installed this month at GenesisCare's center at St Vincent's Hospital in Sydney, New South Wales, with the first patients anticipated to begin treatment before the end of the year. The deployment of the ZAP-X platform will enhance GenesisCare's neuro-oncology treatment capabilities in Sydney, enabling it to deliver dedicated stereotactic radiosurgery (SRS). Previously, SRS patients were primarily treated using cobalt-60 systems and multi-purpose radiotherapy linear accelerators. The ZAP-X, in contrast, is a dedicated platform designed for non-inv...

2026-09-09

Alpha-9 Oncology Initiates Phase 1 Clinical Trial of GRPR-Targeted Radiotherapy, First Patient Dosed

Alpha-9 Oncology, a U.S. clinical-stage radiopharmaceutical company, recently announced that the first patient has been dosed in its Phase 1 clinical trial evaluating two GRPR-targeted radiopharmaceuticals. The study involves the actinium-225-labeled compound 225Ac-A9-0642 and the lutetium-177-labeled compound 177Lu-A9-0631, primarily enrolling patients with breast cancer and other solid tumors, with data expected to be released by the end of 2027. According to the company, both 225Ac-A9-0642 and 177Lu-A9-0631 target the gastrin-releasing peptide receptor (GRPR). GRPR is considered a solid tumor-associated target with potential clinical value in breast cancer and other solid tumors. 225Ac-A9-0642 is Alpha-9's first actinium-225 GRPR-targeted compound to enter clinical evaluation...

2026-09-09

South Korea's DuChemBio to Build Country's First Radiopharmaceutical CDMO Plant

South Korean radiopharmaceutical therapy company DuChemBio will build the country's first contract development and manufacturing organization (CDMO) plant dedicated to radiopharmaceuticals, in response to growing demand for radiopharmaceuticals used in the diagnosis and treatment of cancer and neurological diseases. DuChemBio is a subsidiary of healthcare distributor Geo-Young Group. The company recently signed an investment agreement with North Jeolla Province and the city of Jeongeup to invest KRW 34.3 billion (approximately USD 25.5 million) in building a new plant in Jeongeup. The company stated that this is the largest investment since Geo-Young acquired DuChemBio. According to the plan, the new facility will integrate radioisotope production...

2026-09-08

Argentina Plans to Commission RA-10 Multipurpose Reactor in 2027

Argentina's National Atomic Energy Commission (CNEA) and the Nuclear Affairs Secretariat recently stated that the RA-10 multipurpose research reactor at the Ezeiza Atomic Centre is planned to begin commissioning before the end of this year, with the goal of achieving operation in 2027. (Image source: CNEA) According to the project site, RA-10 is currently in its final phase, with approximately 530 workers completing the remaining construction and system testing in preparation for subsequent reactor commissioning and operation. The project is currently about 96% complete overall. RA-10 is a 30 MW open-pool multipurpose research reactor that will provide products and services to the medical, scientific, technological, and industrial sectors once completed. Among these, molybdenum-99 will be one of its key products...

2026-09-08

Cancer Hospital of the First Hospital of Jilin University Established, Granted Configuration Permit for Heavy Ion Radiotherapy System

Recently, the 7th Bethune Conference on New Advances in Cancer Treatment was held in Changchun, Jilin Province. The conference coincided with the 80th anniversary of Jilin University and the 20th anniversary of the Cancer Center of the First Hospital of Jilin University, aiming to establish a high-level academic exchange platform and promote the continuous improvement of cancer diagnosis and treatment capabilities in the three northeastern provinces. During the conference, the inauguration ceremony of the Cancer Hospital of the First Hospital of Jilin University was also held. According to reports, the newly established Cancer Hospital will, based on the coordinated development of the original Cancer Center, integrate three advantageous disciplines—oncology, hematology, and radiation oncology—further improve the multidisciplinary collaborative diagnosis and treatment model, promote smoother connections in cancer diagnosis and treatment processes, and enhance comprehensive treatment capabilities for difficult cancers. The conference also...

2026-09-08

Japanese Research Uses Tau PET to Reveal Association with Symptom Progression in Progressive Supranuclear Palsy

A research team at the National Institutes for Quantum Science and Technology (QST) in Japan recently announced findings from a study on progressive supranuclear palsy (PSP). Using their self-developed tau PET imaging technology, the researchers conducted follow-up scans on the same group of PSP patients at approximately one-year intervals, confirming for the first time in living brains that the faster tau protein accumulates in the globus pallidus region deep within the brain, the faster patient symptoms progress. The findings were published on September 5, 2026, in the international neurology journal *Movement Disorders*. Characteristic tau protein accumulation regions in PSP Progressive supranuclear palsy is a progressive neurodegenerative disease occurring in middle-aged and older adults, with common manifestations including increased risk of falls, difficulty with movement, eye movement disorders, postural instability, and cognitive dysfunction. There is currently no therapy that can cure or halt disease progression; therefore, establishing biomarkers that can objectively reflect disease changes and treatment efficacy has been a critical issue in drug development. Previous autopsy studies have shown that abnormal tau protein accumulation in the brains of PSP patients is an important pathological feature, particularly concentrated in deep brain regions such as the globus pallidus and midbrain. However, autopsy samples cannot be used for long-term dynamic observation, and how tau protein accumulation changes over time and how it corresponds to symptom progression had previously remained unclear. In recent years, positron emission tomography (PET) has made it possible to observe tau protein in living brains, but existing studies have mainly shown that tau protein increases over time without sufficiently demonstrating a direct association between these changes and symptom worsening. In this study, the research team used the PET radiopharmaceutical 18F-PM-PBB3 developed by QST, namely florzolotau (18F), to perform two PET examinations on 26 PSP patients and 10 healthy controls, conducted at baseline and approximately one year later. The researchers combined 57 brain regions identified by MRI and performed multivariate analysis of PET signal changes to identify PSP-related tau protein accumulation regions and their spread over time. The results showed that at baseline, tau protein in PSP patients was primarily accumulated in subcortical regions such as the globus pallidus and midbrain, consistent with previous reports. Follow-up imaging at one year showed further increases in tau protein accumulation in the globus pallidus, along with marked increases in tau accumulation in the frontoparietal lobes and cerebellar white matter, suggesting that during the course of PSP, tau protein may spread from deep brain regions to the cerebral cortex and cerebellar-related areas. The research team further focused on Richardson's syndrome, the most typical and common subtype of PSP. This subtype typically progresses rapidly, and the 18 patients with this subtype included in this study showed significant increases in PSP rating scale scores within one year. The analysis found that changes in tau protein accumulation in the globus pallidus showed the strongest correlation with the degree of symptom progression; that is, the faster tau protein accumulated in this region, the more pronounced the worsening of patient symptoms. Analyses of individual patients likewise showed that globus pallidus tau protein accumulation can reflect the course of PSP from mild to severe stages. The researchers believe that serial tau PET imaging has the potential to serve as a novel imaging biomarker for assessing PSP disease progression, and also provides a basis for tau-targeted therapeutic strategies: if future therapies can inhibit tau protein accumulation, it may be possible to slow symptom progression. Next steps still require longer-term follow-up in a larger number of patients to validate the relationship between changes in tau protein accumulation and overall symptom progression and treatment response. The imaging assessment method established in this study may not only be used for disease monitoring and clinical trial efficacy evaluation in PSP, but may also be extended to research on other tau protein-related neurodegenerative diseases and dementias, providing new technical support for the diagnosis and therapeutic development of related diseases.

2026-09-07